Meglumine in Combination with Another Therapeutic

Abstract

The invention relates to a method of treating or preventing a condition in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof. The invention further relates to a method of improving a physiological function in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof.

What is claimed is: 
     
         1 . A composition comprising meglumine or a salt thereof and a therapeutic agent selected from the group consisting of α-glucosidase inhibitors, lipase inhibitors, sulfonyl ureas, meglitinides, biguanides, thiazolidinediones, pramlintide, incretin mimetics, DPP-IV inhibitors, a salt thereof, and any combinations thereof. 
     
     
         2 . The composition of  claim 1 , wherein the therapeutic agent comprises metformin. 
     
     
         3 . The composition of  claim 1 , further comprising:
 a first amount of a sweet-tasting compound,   wherein the composition is suitable for oral consumption by a subject;   wherein the sweetness of the composition is equivalent to the sweetness of a second amount of the sweet-tasting compound,   further wherein the composition is healthier, is less toxic or has fewer undesirable physiological effects in the subject than the second amount of the sweet-tasting compound.   
     
     
         4 . The composition of  claim 3 , wherein the sweet-tasting compound comprises glucose, dextrose, high-fructose corn syrup, mannitol, sorbitol, stevia, xylitol, acesulfame potassium, alitame, aspartame, a salt of aspartame-acesulfame, cyclamate, dulcin, glucin, neohesperidin dihydrochalcone, neotame, saccharin, sucralose, or any combinations thereof. 
     
     
         5 . The composition of  claim 3 , wherein the subject is a mammal. 
     
     
         6 . The composition of  claim 3 , wherein the mammal is a human. 
     
     
         7 . The composition of  claim 1 , wherein the meglumine salt is formed between meglumine and an acid selected from the group consisting of sulfate, hydrogen sulfate, hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric, phosphoric, formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic, methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, trifluoromethanesulfonic, 2-hydroxyethane sulfonic, p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, β-hydroxybutyric, salicylic, galactaric, and galacturonic acid. 
     
     
         8 . A method, comprising administering the composition of  claim 1  to a subject, wherein the composition is administered to the subject by a route selected from the group consisting of inhalational, oral, rectal, vaginal, parenteral, topical, transdermal, pulmonary, intranasal, buccal, ophthalmic, intrathecal, parenteral, intravenous, and any combinations thereof. 
     
     
         9 . The method of  claim 8 , wherein the composition is administered to the subject at a frequency selected from the group consisting of once a day, twice a day, three times a day, four times a day, once a week, twice a week, three times a week, four times a week, once a month, twice a month, and any combinations thereof. 
     
     
         10 . The method of  claim 8 , wherein the composition is administered to the subject at a dosage ranging from about 1 ng/kg/application to about 100 g/kg/application. 
     
     
         11 . The method of  claim 10 , wherein the composition is administered to the subject at a dosage ranging from about 1 ng/kg/application to about 100 mg/kg/application. 
     
     
         12 . The method of  claim 8 , wherein the composition is administered to the subject as a controlled-release formulation. 
     
     
         13 . The method of  claim 8 , wherein the subject is a mammal. 
     
     
         14 . The method of  claim 13 , wherein the mammal is a human. 
     
     
         15 . The method of  claim 8 , wherein the meglumine salt is formed between meglumine and an acid selected from the group consisting of sulfate, hydrogen sulfate, hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric, phosphoric, formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic, methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, trifluoromethanesulfonic, 2-hydroxyethanesulfonic, p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, β-hydroxybutyric, salicylic, galactaric, and galacturonic acid.